The advent of sodium-glucose 2 transporter (SGLT2) inhibitors offers the opportunity to substantially retard DKD progression and ameliorate the development of cardiovascular disease burden, with greater benefit being derived from earlier intervention facilitated by referral at lower CKD stages [52]. Here, SLC5A2 is linked to diabetic kidney disease.